Aetna modified CPB 0495 covering hematopoietic cell transplantation for Hodgkin's Disease, effective December 11, 2025. Here's what billing teams need to know.
Aetna, a CVS Health company, updated its Hodgkin's Disease transplant coverage policy under CPB 0495 in the Aetna system. The update clarifies medical necessity criteria for both autologous and allogeneic hematopoietic cell transplantation (HCT), including reduced-intensity conditioning protocols. Primary CPT codes affected include 38240 and 38241 for transplantation, 38205 and 38206 for cell harvesting, and 86813, 86817, and 86821 for HLA typing. If your team bills any of these codes for Aetna members with Hodgkin's Disease, read this before your next authorization request.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Hematopoietic Cell Transplantation for Hodgkin's Disease |
| Policy Code | CPB 0495 |
| Change Type | Modified |
| Effective Date | December 11, 2025 |
| Impact Level | High |
| Specialties Affected | Hematology/Oncology, Bone Marrow Transplant Programs, Radiation Oncology |
| Key Action | Confirm transplanting institution selection criteria are documented in prior auth packages before December 11, 2025 |
Aetna Hodgkin's Disease Transplant Coverage Criteria and Medical Necessity Requirements 2025
CPB 0495 Aetna establishes two separate coverage tracks for HCT in Hodgkin's Disease — one for autologous transplantation and one for allogeneic. The distinction matters enormously for reimbursement and prior authorization.
Autologous HCT (CPT 38241, 38206, 38232)
Aetna considers autologous HCT medically necessary when the member meets the transplanting institution's own selection criteria. That's the first and cleanest path to approval.
If the transplanting institution has no formal selection criteria on file, Aetna applies its own two-part test. The member must be in primary induction failure or beyond first remission, and the member must be free of serious organ dysfunction per the transplanting institution's evaluation. Both conditions must be met. Meeting only one will not satisfy this coverage policy.
The real issue here: if your transplant center doesn't have documented institutional selection criteria, you're billing under Aetna's fallback criteria every time. That increases denial risk. Get your institution's criteria formalized and reference them explicitly in every prior auth submission.
Allogeneic HCT (CPT 38240, 38205, 38230)
The allogeneic path is broader but also more specific. Aetna considers allogeneic HCT medically necessary for members with relapsed HD — including those who relapsed after a prior autologous HCT — and for primary refractory HD. This is notable: a failed auto-HCT does not close the door on allogeneic coverage.
The same two-track structure applies. Transplanting institution criteria take precedence. Without them, Aetna requires primary induction failure or post-first-remission status, plus absence of serious organ dysfunction.
Reduced-Intensity Conditioning ("Mini-Transplant")
Aetna specifically covers non-myeloablative allogeneic HCT — commonly called a "mini-transplant" or reduced-intensity conditioning (RIC) transplant — for members with relapsed or primary refractory HD who are eligible for conventional allografting. This is covered under the same medical necessity framework as standard allogeneic HCT. If your team bills for RIC transplants and you've been treating these as a gray area for prior authorization, this policy language settles it.
Aetna Hodgkin's Disease Transplant Exclusions and Non-Covered Indications
Tandem transplants — also called sequential transplants — are the single explicit exclusion in this coverage policy. Aetna considers tandem HCT for Hodgkin's Disease experimental, investigational, and unproven. There is no medical necessity pathway for this approach under CPB 0495.
If your program is exploring tandem protocols for HD patients, those cases will not clear medical necessity review under this policy. There is no fallback criteria set that makes tandem transplants approvable. Don't submit these as standard HCT claims hoping for different results — claim denial is essentially guaranteed if the documentation reflects a tandem approach.
If you believe a specific member has a compelling case, talk to your compliance officer and consider a formal appeals strategy before you bill. This is not a case where billing first and appealing later is a viable workflow.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Autologous HCT — member meets transplanting institution criteria | Covered | 38241, 38206, 38232 | Institution criteria must be documented |
| Autologous HCT — primary induction failure or beyond first remission, no serious organ dysfunction | Covered | 38241, 38206, 38232 | Fallback when institution has no criteria; both conditions required |
| Allogeneic HCT — relapsed HD (including post-auto-HCT relapse), institution criteria met | Covered | 38240, 38205, 38230 | Covers persistent disease after auto-HCT |
| Allogeneic HCT — primary refractory HD, institution criteria met | Covered | 38240, 38205, 38230 | Institution criteria take precedence |
| Allogeneic HCT — relapsed or refractory HD, no institution criteria | Covered | 38240, 38205, 38230 | Must meet both Aetna fallback criteria |
| Non-myeloablative allogeneic HCT (RIC/"mini-transplant") — relapsed or refractory HD | Covered | 38240, 38205 | Must be eligible for conventional allografting |
| Tandem (sequential) transplants for HD | Experimental / Not Covered | 38241, 38240 | No medical necessity pathway; claim denial expected |
| HLA typing for donor matching | Covered (if criteria met) | 86813, 86817, 86821 | Covered as part of transplant workup |
| Cell preparation and processing | Covered (if criteria met) | 38210, 38211, 38212, 38213 | Covered when underlying transplant is covered |
| Donor search and cell acquisition | Covered (if criteria met) | 38204 | For allogeneic cases with matched donor |
Aetna Hematopoietic Cell Transplantation Billing Guidelines and Action Items 2025
These are the steps your billing and clinical teams should take before the effective date of December 11, 2025.
| # | Action Item |
|---|---|
| 1 | Audit your transplanting institution's documented selection criteria. Aetna's first test in every coverage pathway is whether the member meets institutional criteria. If your program can't produce that documentation on demand, every authorization for CPT 38240 and 38241 defaults to Aetna's fallback criteria. Formalize your selection criteria now and reference them in every prior auth package. |
| 2 | Flag any active tandem transplant cases for Hodgkin's Disease. These will not pass medical necessity review under CPB 0495. If a member is mid-protocol and billing has already started, loop in your compliance officer and billing consultant before December 11, 2025 to assess your exposure. |
| 3 | Update your prior authorization templates for allogeneic HCT. Make sure your auth requests for CPT 38240 explicitly state the disease status — relapsed, persistent post-auto-HCT, or primary refractory. Aetna's coverage policy differentiates these. Vague clinical language increases denial risk. |
| 4 | Confirm RIC transplant cases are documented as "eligible for conventional allografting." Aetna covers non-myeloablative allogeneic HCT only when the member meets conventional allografting eligibility. Your clinical documentation needs to state this explicitly — not just describe the RIC approach — to support reimbursement for CPT 38240 in these cases. |
| 5 | Verify HLA typing codes are included in your transplant billing package. CPT 86813 (HLA typing, A, B or C), 86817 (DR/DQ, multiple antigens), and 86821 (mixed lymphocyte culture) are covered when selection criteria are met. These codes are frequently under-billed or omitted from transplant claims. Check your charge capture for each allogeneic case. |
| 6 | Review cell harvesting and preparation charge capture. CPT 38204 (donor search and cell acquisition), 38210 through 38213 (transplant preparation), 38230 (bone marrow harvesting, allogeneic), and 38232 (bone marrow harvesting, autologous) are covered under this billing policy when criteria are met. Missing these on a claim leaves real reimbursement on the table. |
| 7 | If your program has complex cases — post-auto-HCT patients being evaluated for allogeneic — document the prior transplant history in the auth request. CPB 0495 explicitly covers allogeneic HCT for members who relapsed after an autologous transplant. If that history isn't in your prior auth documentation, Aetna's reviewers may not make the connection. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Hematopoietic Cell Transplantation Under CPB 0495
Covered CPT Codes (When Selection Criteria Are Met)
| Code | Description |
|---|---|
| 38204 | Management of recipient hematopoietic progenitor cell donor search and cell acquisition |
| 38205 | Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; allogeneic |
| 38206 | Blood-derived hematopoietic progenitor cell harvesting; autologous |
| 38210 | Transplant preparation of hematopoietic progenitor cells; specific cell depletion with harvest, T-cell depletion |
| 38211 | Transplant preparation; tumor cell depletion |
| 38212 | Transplant preparation; red blood cell removal |
| 38213 | Transplant preparation; platelet depletion |
| 38230 | Bone marrow harvesting for transplantation; allogeneic |
| 38232 | Bone marrow harvesting for transplantation; autologous |
| 38240 | Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor |
| 38241 | Hematopoietic progenitor cell (HPC); autologous transplantation |
| 86813 | HLA typing; A, B or C multiple antigens |
| 86817 | HLA typing; DR/DQ, multiple antigens |
| 86821 | HLA typing; lymphocyte culture, mixed (MLC) |
ICD-10-CM Diagnosis Codes
The policy references 100 ICD-10-CM codes. The policy data provided does not include the full code list with descriptions. Contact Aetna directly or check CPB 0495 at the Aetna provider portal for the complete ICD-10-CM code set applicable to Hodgkin's Disease diagnoses under this policy.
Get the Full Picture for CPT 38241
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.